{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T07:47:19Z","timestamp":1774079239693,"version":"3.50.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Novel tuberculosis (TB) vaccines should be safe and effective in populations infected with Mycobacterium tuberculosis (M.tb) and\/or HIV for effective TB control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the safety and immunogenicity of MVA85A, a novel TB vaccine, among M.tb- and\/or HIV-infected persons in a setting where TB and HIV are endemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An open-label, phase IIa trial was conducted in 48 adults with M.tb and\/or HIV infection. Safety and immunogenicity were analyzed up to 52 weeks after intradermal vaccination with 5 \u00d7 107 plaque-forming units of MVA85A. Specific T-cell responses were characterized by IFN-\u03b3 enzyme-linked immunospot and whole blood intracellular cytokine staining assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>MVA85A was well tolerated and no vaccine-related serious adverse events were recorded. MVA85A induced robust and durable response of mostly polyfunctional CD4+ T cells, coexpressing IFN-\u03b3, tumor necrosis factor-\u03b1, and IL-2. Magnitudes of pre- and postvaccination T-cell responses were lower in HIV-infected, compared with HIV-uninfected, vaccinees. No significant effect of antiretroviral therapy on immunogenicity of MVA85A was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MVA85A was safe and immunogenic in persons with HIV and\/or M.tb infection. These results support further evaluation of safety and efficacy of this vaccine for prevention of TB in these target populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201108-1548oc","type":"journal-article","created":{"date-parts":[[2012,1,26]],"date-time":"2012-01-26T22:10:54Z","timestamp":1327615854000},"page":"769-778","source":"Crossref","is-referenced-by-count":77,"title":["A Phase IIa Trial of the New Tuberculosis Vaccine, MVA85A, in HIV- and\/or\n                    <i>Mycobacterium tuberculosis<\/i>\n                    \u2013infected Adults"],"prefix":"10.1093","volume":"185","author":[{"given":"Thomas J.","family":"Scriba","sequence":"first","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Tameris","sequence":"additional","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Smit","sequence":"additional","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"van der Merwe","sequence":"additional","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Jane","family":"Hughes","sequence":"additional","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blessing","family":"Kadira","sequence":"additional","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katya","family":"Mauff","sequence":"additional","affiliation":[{"name":"Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sizulu","family":"Moyo","sequence":"additional","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Brittain","sequence":"additional","affiliation":[{"name":"Jenner Institute, Oxford University, Oxford, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Lawrie","sequence":"additional","affiliation":[{"name":"Jenner Institute, Oxford University, Oxford, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Humphrey","family":"Mulenga","sequence":"additional","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwou","family":"de Kock","sequence":"additional","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lebohang","family":"Makhethe","sequence":"additional","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esme","family":"Janse van Rensburg","sequence":"additional","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Gelderbloem","sequence":"additional","affiliation":[{"name":"Aeras, Rondebosch, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Veldsman","sequence":"additional","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Hatherill","sequence":"additional","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"Geldenhuys","sequence":"additional","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian V. S.","family":"Hill","sequence":"additional","affiliation":[{"name":"Jenner Institute, Oxford University, Oxford, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Hawkridge","sequence":"additional","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory D.","family":"Hussey","sequence":"additional","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem A.","family":"Hanekom","sequence":"additional","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"McShane","sequence":"additional","affiliation":[{"name":"Jenner Institute, Oxford University, Oxford, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Mahomed","sequence":"additional","affiliation":[{"name":"South African Tuberculosis Vaccine Initiative, Institute of Infectious Diseases and Molecular Medicine, and School of Child and Adolescent Health, and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,4,1]]},"reference":[{"key":"2026032101140351200_bib1","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1001\/archinte.163.9.1009","article-title":"The growing burden of tuberculosis: global trends and interactions with the HIV epidemic","volume":"163","author":"Corbett","year":"2003","journal-title":"Arch Intern Med"},{"key":"2026032101140351200_bib2","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1097\/QAD.0b013e32832d3b6d","article-title":"Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa","volume":"23","author":"Lawn","year":"2009","journal-title":"AIDS"},{"key":"2026032101140351200_bib3","doi-asserted-by":"crossref","first-page":"13980","DOI":"10.1073\/pnas.0901720106","article-title":"Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics","volume":"106","author":"Abu-Raddad","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026032101140351200_bib4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1098\/rsif.2007.1138","article-title":"Eliminating human tuberculosis in the twenty-first century","volume":"5","author":"Dye","year":"2008","journal-title":"J R Soc Interface"},{"key":"2026032101140351200_bib5","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/ije\/22.6.1154","article-title":"Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis","volume":"22","author":"Rodrigues","year":"1993","journal-title":"Int J Epidemiol"},{"key":"2026032101140351200_bib6","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(06)68507-3","article-title":"Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness","volume":"367","author":"Trunz","year":"2006","journal-title":"Lancet"},{"key":"2026032101140351200_bib7","article-title":"Issues relating to the use of BCG in immunization programmes: a discussion document. Geneva, Switzerland: World Health Organization; 1999","author":"Fine"},{"key":"2026032101140351200_bib8","article-title":"Global tuberculosis control","author":"World Health Organization","year":"2010"},{"key":"2026032101140351200_bib9","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/adc.2011.214494","article-title":"Prospects for elimination of childhood tuberculosis: the role of new vaccines","volume":"96","author":"Hatherill","year":"2011","journal-title":"Arch Dis Child"},{"key":"2026032101140351200_bib10"},{"key":"2026032101140351200_bib11","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1164\/rccm.200809-1486OC","article-title":"Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis\u2013infected individuals","volume":"179","author":"Sander","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101140351200_bib12","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/QAD.0b013e3283350f1b","article-title":"Prevention of tuberculosis in bacille Calmette-Gu\u00e9rin\u2013primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine","volume":"24","author":"von Reyn","year":"2010","journal-title":"AIDS"},{"key":"2026032101140351200_bib13","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.1016\/j.vaccine.2010.09.041","article-title":"Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania","volume":"28","author":"Lahey","year":"2010","journal-title":"Vaccine"},{"key":"2026032101140351200_bib14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/eji.200939754","article-title":"Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells","volume":"40","author":"Scriba","year":"2010","journal-title":"Eur J Immunol"},{"key":"2026032101140351200_bib15","doi-asserted-by":"crossref","first-page":"e5950","DOI":"10.1371\/journal.pone.0005950","article-title":"Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection\u2014a quantitative review","volume":"4","author":"Korenromp","year":"2009","journal-title":"PLoS ONE"},{"key":"2026032101140351200_bib16","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1086\/590185","article-title":"Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa","volume":"198","author":"Hawkridge","year":"2008","journal-title":"J Infect Dis"},{"key":"2026032101140351200_bib17","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jac\/dkl092","article-title":"HIV-1 viral load blips are of limited clinical significance","volume":"57","author":"Lee","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2026032101140351200_bib18","first-page":"157","article-title":"Update on HIV-1 viral load blips","volume":"1","author":"Nettles","year":"2006","journal-title":"Curr Opin HIV AIDS"},{"key":"2026032101140351200_bib19","first-page":"61","article-title":"Immunization of children at risk of infection with human immunodeficiency virus","volume":"81","author":"Moss","year":"2003","journal-title":"Bull World Health Organ"},{"key":"2026032101140351200_bib20","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1086\/318706","article-title":"A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes","volume":"32","author":"El-Sadr","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2026032101140351200_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/bmj.1.1568.125","article-title":"A further communication on a remedy for tuberculosis","volume":"1","author":"Koch","year":"1891","journal-title":"BMJ"},{"key":"2026032101140351200_bib22","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1128","article-title":"Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans","volume":"10","author":"McShane","year":"2004","journal-title":"Nat Med"},{"key":"2026032101140351200_bib23","doi-asserted-by":"crossref","first-page":"e2921","DOI":"10.1371\/journal.pone.0002921","article-title":"Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa","volume":"3","author":"Brookes","year":"2008","journal-title":"PLoS ONE"},{"key":"2026032101140351200_bib24","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1093\/infdis\/jir195","article-title":"Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants","volume":"203","author":"Scriba","year":"2011","journal-title":"J Infect Dis"},{"key":"2026032101140351200_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002461","article-title":"Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants","volume":"3","author":"Ota","year":"2011","journal-title":"Sci Transl Med"},{"key":"2026032101140351200_bib26","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1084\/jem.20100090","article-title":"Preferential infection and depletion of Mycobacterium tuberculosis\u2013specific CD4 T cells after HIV-1 infection","volume":"207","author":"Geldmacher","year":"2010","journal-title":"J Exp Med"},{"key":"2026032101140351200_bib27","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1128\/IAI.01126-10","article-title":"HIV-1\/Mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis?","volume":"79","author":"Diedrich","year":"2011","journal-title":"Infect Immun"},{"key":"2026032101140351200_bib28","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1164\/rccm.200907-1011OC","article-title":"HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria","volume":"180","author":"Kalsdorf","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101140351200_bib29","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1164\/rccm.201003-0334OC","article-title":"Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis, following BCG vaccination of newborns","volume":"182","author":"Kagina","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101140351200_bib30","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.4049\/jimmunol.1101122","article-title":"Functional capacity of Mycobacterium tuberculosis\u2013specific T cell responses in humans is associated with mycobacterial load","volume":"187","author":"Day","year":"2011","journal-title":"J Immunol"},{"key":"2026032101140351200_bib31","doi-asserted-by":"crossref","first-page":"12434","DOI":"10.1073\/pnas.0703510104","article-title":"Poor correlation between BCG vaccination\u2013induced T cell responses and protection against tuberculosis","volume":"104","author":"Mittrucker","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026032101140351200_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm.2285","article-title":"A multistage tuberculosis vaccine that confers efficient protection before and after exposure","volume":"17","author":"Aagaard","year":"2011","journal-title":"Nat Med"},{"key":"2026032101140351200_bib33","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/eji.200636128","article-title":"Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis","volume":"36","author":"Bennekov","year":"2006","journal-title":"Eur J Immunol"},{"key":"2026032101140351200_bib34","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.4049\/jimmunol.181.7.4955","article-title":"Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice","volume":"181","author":"Forbes","year":"2008","journal-title":"J Immunol"},{"key":"2026032101140351200_bib35","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1371\/journal.pmed.0050145","article-title":"Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations","volume":"5","author":"Hanekom","year":"2008","journal-title":"PLoS Med"},{"key":"2026032101140351200_bib36","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1086\/322042","article-title":"Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in northern Malawi","volume":"184","author":"Black","year":"2001","journal-title":"J Infect Dis"},{"key":"2026032101140351200_bib37","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(02)08353-8","article-title":"BCG-induced increase in interferon-\u03b3 response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies","volume":"359","author":"Black","year":"2002","journal-title":"Lancet"},{"key":"2026032101140351200_bib38","doi-asserted-by":"crossref","first-page":"e5934","DOI":"10.1371\/journal.pone.0005934","article-title":"Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A","volume":"4","author":"Whelan","year":"2009","journal-title":"PLoS ONE"},{"key":"2026032101140351200_bib39","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/IAI.70.2.672-678.2002","article-title":"Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis","volume":"70","author":"Brandt","year":"2002","journal-title":"Infect Immun"},{"key":"2026032101140351200_bib40","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.4049\/jimmunol.172.5.3337","article-title":"Effects of sustained HIV-1 plasma viremia on HIV-1 Gag-specific CD4+ T cell maturation and function","volume":"172","author":"Palmer","year":"2004","journal-title":"J Immunol"},{"key":"2026032101140351200_bib41","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1084\/jem.20031598","article-title":"HIV-1 viremia prevents the establishment of interleukin 2\u2013producing HIV-specific memory CD4+ T cells endowed with proliferative capacity","volume":"198","author":"Younes","year":"2003","journal-title":"J Exp Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/185\/7\/769\/67249732\/ajrccm_185_7_769.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/185\/7\/769\/67249732\/ajrccm_185_7_769.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:14:10Z","timestamp":1774070050000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/185\/7\/769\/8508102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,1]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2012,4,1]]},"published-print":{"date-parts":[[2012,4,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201108-1548oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,4]]},"published":{"date-parts":[[2012,4,1]]}}}